🔥Recent advances in #neuroimaging of #Alzheimers disease 🧠✨

dx.doi.org/10.1002/alz....

➡️ Valuable resource for both researchers & clinicians!
➡️ ATNIV biomarkers, staging, connectomics & more
➡️ Plus: how are sex & country represented in first/last authorship?

@istaart.bsky.social Neuroimaging PIA

Neuroimaging PIA - RELAY Video Podcast YouTube video by Dementia Researcher

🎙️ Plasma biomarkers, PET, and MRI – @alexapb.bsky.social explains how these tools are reshaping Alzheimer’s diagnostics in the @istaart.bsky.social Neuroimaging PIA. Listen now or Watch the last episode in this series.

Watch: youtu.be/x2ifaepExB0
Listen: pod.fo/e/2fde7c

I strongly support the NIH Diversity Supplement Program. Addressing the severe lack of diversity among biomedical researchers improves the quality of research. It's not a level playing field. This program helps restore equity through mentored training. Rescinding this program is a big mistake

‘Never seen anything like this’: Trump’s team halts NIH meetings and travel In an unprecedented move, research-grant reviews have been suspended indefinitely at the world’s largest public funder of biomedical research.

www.nature.com/articles/d41...
I’ve been trying to not get worked up with every crazy thing that has happened with the election, but this is likely something to worry about. Really shows how an unserious person Trump is.

Are my kids the only ones who find the winter solstice the IDEAL time to play with water balloons?

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer’s disease INTRODUCTION Alzheimer disease (AD)-modifying therapies are approved for treatment of early-symptomatic AD. Autosomal dominant AD (ADAD) provides a unique opportunity to test therapies in presymptomat...

New preprint out: using data from DIAN, we estimate what sample sizes would be needed for various biomarker outcomes in clinical trials of autosomal dominant Alzheimer's disease: www.medrxiv.org/content/10.1...